1. 127P Phase I study of fianlimab: A human lymphocyte activation gene-3 (LAG-3) monoclonal antibody, in combination with cemiplimab in advanced NSCLC. (December 2022) Authors: Cho, B.C.; Dy, G.; Kim, T.M.; Sarker, D.; Hamid, O.; Williamson, S.; Sang-We, K.; Hatim, H.; Chen, S.; Mani, J.; Jankovic, V.; Paccaly, A.J.; Masinde, S.; Lowy, I.; Brennan, L.; Gullo, G. Journal: Immuno-oncology technology Issue: Volume 16(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. CLINICAL ACTIVITY OF REGN1979, AN ANTI‐CD20 X ANTI‐CD3 BISPECIFIC ANTIBODY (AB) IN PATIENTS (PTS) WITH (W/) RELAPSED/REFRACTORY (R/R) B‐CELL NON‐HODGKIN LYMPHOMA (B‐NHL). (12th June 2019) Authors: Topp, M.S.; Arnason, J.; Advani, R.; Brown, J.R.; Allan, J.; Ansell, S.; O'Brien, S.; Chavez, J.; Duell, J.; Rosenwald, A.; Charnas, R.; Ambati, S.R.; Adriaens, L.; Ufkin, M.; Zhu, M.; Li, J.; Gasparini, P.; Jankovic, V.; Fiaschi, N.; Zhang, W. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 90 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗